{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T17:40:10Z","timestamp":1739209210053,"version":"3.37.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:p>Bilateral oophorectomy is one method of hormone suppression for premenopausal patients with hormone receptor-positive breast cancer. Such specimens could, in theory, harbor occult early ovarian cancer and\/or metastatic breast cancer but guidelines for tissue sampling for pathologic examination remain to be addressed. Therefore, we evaluated oophorectomy specimens from 166 patients who underwent ovarian ablation for hormone receptor-positive breast cancer. Results of germline genetic testing were documented by the surgeon in only 31.3% of the pathology specimen requisition forms, whereas that information was available for 81.3% of patients elsewhere in the electronic medical records. All but 5.2% tested negative for a hereditary ovarian cancer gene pathogenic variant before oophorectomy. Complete tissue sampling was performed in 77.1% of the cases and representative sampling in the remainder. No cases of ovarian cancer were observed. Ovarian metastasis of breast cancer was identified in 9.6% of patients, all of whom were already known to have advanced-stage disease. The number of tissue cassettes per ovary required for complete tissue submission was on average three times higher than that for representative tissue sampling (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.01) and ranged up to 20 cassettes per ovary when multiple follicle cysts were present. We propose that guidelines for tissue sampling in this context be defined by a combination of hereditary risk and macroscopic examination; representative sampling is reasonable for macroscopically normal ovaries in hormone receptor-positive breast cancer patients whose germline genetic testing is negative. Positive genetic test results merit complete tissue submission even if macroscopically normal. This strategy balances the goals of early ovarian cancer detection and optimal resource utilization. However, it depends on clear documentation of genetic test results. Our study demonstrates that many opportunities remain to close gaps in the communication of genetic test results by clinicians submitting oophorectomy specimens for pathologic evaluation.<\/jats:p>","DOI":"10.1097\/pgp.0000000000001055","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T19:00:14Z","timestamp":1720033214000},"page":"174-181","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of Occult Ovarian Cancer and Metastatic Breast Cancer in Ovarian Ablation Specimens of Patients With Hormone Receptor-Positive Breast Cancer: Implications for Tissue Sampling Strategies, Early Ovarian Cancer Detection and Resource Utilization"],"prefix":"10.1097","volume":"44","author":[{"given":"Anjali","family":"Walia","sequence":"first","affiliation":[{"name":"School of Medicine, University of California, San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas R.","family":"Ladwig","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of California, San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie S.","family":"Mak","sequence":"additional","affiliation":[{"name":"Cancer Risk Program, University of California, San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph T.","family":"Rabban","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of California, San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"key":"R1-20250210","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1001\/jama.2017.21926","article-title":"Screening for ovarian cancer: US Preventive Services Task Force recommendation statement","volume":"319","author":"Grossman","year":"2018","journal-title":"JAMA"},{"key":"R4-20250210","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","article-title":"The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome","volume":"30","author":"Medeiros","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"R5-20250210","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ygyno.2011.01.031","article-title":"Correlation of macroscopic and microscopic pathology in risk-reducing salpingo-oophorectomy: implications for intraoperative specimen evaluation","volume":"121","author":"Rabban","year":"2011","journal-title":"Gynecol Oncol"},{"key":"R6-20250210","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/PAS.0000000000000199","article-title":"Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery","volume":"38","author":"Rabban","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R7-20250210","first-page":"CD013538","article-title":"Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer","volume":"3","author":"Bui","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"suppl 1","key":"R10-20250210","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1097\/PGP.0000000000000908","article-title":"Data set for the reporting of ovarian, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)","volume":"41","author":"Gilks","year":"2022","journal-title":"Int J Gynecol Pathol"},{"key":"R11-20250210","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/annonc\/mdi085","article-title":"Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy","volume":"16","author":"Arriagada","year":"2005","journal-title":"Ann Oncol"},{"key":"R12-20250210","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.19.00126","article-title":"Adding ovarian suppression to tamoxifen for premenopausal breast cancer: a randomized phase III trial","volume":"38","author":"Kim","year":"2020","journal-title":"J Clin Oncol"},{"key":"R13-20250210","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N Engl J Med"},{"key":"R14-20250210","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1200\/JCO.1996.14.1.46","article-title":"Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study","volume":"14","author":"Rivkin","year":"1996","journal-title":"J Clin Oncol"},{"key":"R15-20250210","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ijgc-2020-001966","article-title":"Surgical ovarian suppression for adjuvant treatment in hormone receptor-positive breast cancer in premenopausal patients","volume":"31","author":"Oseledchyk","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"R17-20250210","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/PAS.0b013e3182796e27","article-title":"Histologic evaluation of prophylactic hysterectomy and oophorectomy in Lynch syndrome","volume":"37","author":"Karamurzin","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R18-20250210","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ygyno.2013.10.033","article-title":"Prevalence of occult gynecologic malignancy at the time of risk-reducing and nonprophylactic surgery in patients with Lynch syndrome","volume":"132","author":"Lachiewicz","year":"2014","journal-title":"Gynecol Oncol"},{"key":"R19-20250210","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1097\/PAS.0000000000000684","article-title":"Pathologic findings in prophylactic and nonprophylactic hysterectomy specimens of patients with Lynch syndrome","volume":"40","author":"Bartosch","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R20-20250210","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/his.12386","article-title":"Review of findings in prophylactic gynaecological specimens in Lynch syndrome with literature review and recommendations for grossing","volume":"65","author":"Downes","year":"2014","journal-title":"Histopathology"},{"key":"R21-20250210","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/PGP.0000000000000643","article-title":"Prophylactic risk-reducing hysterectomies and bilateral salpingo-oophorectomies in patients with Lynch syndrome: a clinicopathologic study of 29 cases and review of the literature","volume":"39","author":"Fedda","year":"2020","journal-title":"Int J Gynecol Pathol"},{"key":"R23-20250210","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ygyno.2018.01.016","article-title":"Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: a survey of U.S. laboratory practices","volume":"148","author":"Samimi","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R25-20250210","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2147\/CLEP.S206949","article-title":"A systematic review of the international prevalence of BRCA mutation in breast cancer","volume":"11","author":"Armstrong","year":"2019","journal-title":"Clin Epidemiol"},{"key":"R27-20250210","doi-asserted-by":"crossref","first-page":"pky061","DOI":"10.1093\/jncics\/pky061","article-title":"Population frequency of serous tubal intraepithelial carcinoma (STIC) in clinical practice using SEE-Fim protocol","volume":"2","author":"Samimi","year":"2018","journal-title":"JNCI Cancer Spectr"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000001055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T17:02:11Z","timestamp":1739206931000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000001055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000001055","relation":{},"ISSN":["0277-1691","1538-7151"],"issn-type":[{"type":"print","value":"0277-1691"},{"type":"electronic","value":"1538-7151"}],"subject":[],"published":{"date-parts":[[2024,6,26]]}}}